<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910409-0033</DOCNO><DOCID>910409-0033.</DOCID><HL>   Technology Brief -- Genzyme Corp.:   Sale of Drug for Treatment   Of Rare Disease Approved</HL><DATE>04/09/91</DATE><SO>WALL STREET JOURNAL (J), PAGE A6</SO><CO>   GENZ</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>DRUG MANUFACTURERS (DRG)MEDICAL AND BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><GV>FOOD AND DRUG ADMINISTRATION (FDA)</GV><RE>MASSACHUSETTS (MA)</RE><LP>   Genzyme Corp. said that the Food and Drug Administrationapproved the marketing of a new drug for the treatment ofGaucher's disease.   An FDA advisory committee had given the drug a favorablerecommendation last October.</LP><TEXT>   Gaucher's disease is a rare genetic disorder that mostlyaffects people of Eastern European Jewish backgrounds. Itcauses a severely enlarged spleen, anemia, bleeding problemsand orthopedic complications. Ceredase is a modified form ofthe human enzyme whose absence causes the symptoms of thedisorder.   There are an estimated 2,000 to 3,000 Gaucher's patientsin the U.S. and perhaps 10,000 more who have the geneticmutation for the disease but don't show clinical signs.Genzyme, a Cambridge, Mass., biotechnology company, said itexpects to generate $20 million to $40 million in revenuefrom the drug this year.</TEXT></DOC>